Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.

Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005 Mar; 25(3):325-34.

View in: PubMed

subject areas

Adult
Adult
Antineoplastic Agents
Antineoplastic Agents
Benzamides
Benzamides
Bone Marrow Transplantation
Bone Marrow Transplantation
Chronic Disease
Chronic Disease
Cost-Benefit Analysis
Cost-Benefit Analysis
Decision Support Techniques
Decision Support Techniques
Health Care Costs
Health Care Costs
Humans
Humans
Imatinib Mesylate
Imatinib Mesylate
Insurance, Health, Reimbursement
Insurance, Health, Reimbursement
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Male
Male
Markov Chains
Markov Chains
Monte Carlo Method
Monte Carlo Method
Piperazines
Piperazines
Pyrimidines
Pyrimidines

authors with profiles

Grant H Skrepnek